Kazia Therapeutics Prices $40 Million Public Offering

08:00 AM EDT, 08/28/2026 (MT Newswires) -- Kazia Therapeutics (KZIA) said Friday it priced its public offering of 2.58 million American depository shares and accompanying warrants at a combined price of $15.50 each, for gross proceeds of about $40 million. The company said the offering includes series A and series B warrants exercisable at $17.825 and $19.375 per American depository shares, respectively. If fully exercised, the warrants could provide Kazia with an additional $80 million in gross proceeds, the company said. Kazia said it expects the offering to close around Aug. 31 and plans to use the net proceeds to fund clinical development of paxalisib, including ongoing and planned studies in breast cancer, as well as for working capital and general corporate purposes. Leerink Partners and Guggenheim Securities are acting as joint bookrunning managers, the company added.